BIOA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.33
Percentage change 7.38	%

Held by: VTI VXF VTWO VTWG WCEO VTWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	42.97%	Shs Outstand	34.20M	Perf Week	-73.47%
Market Cap	171.94M	Forward P/E	-	EPS next Y	-	Insider Trans	20.66%	Shs Float	20.43M	Perf Month	-78.83%
Income	-	PEG	-	EPS next Q	-0.71	Inst Own	32.41%	Short Float	11.80%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	3.71	Perf Half Y	-
Book/sh	9.17	P/B	0.52	EPS next Y	-	ROA	-	Short Interest	2.41M	Perf Year	-
Cash/sh	9.34	P/C	0.51	EPS next 5Y	-	ROE	-	52W Range	4.23 - 26.62	Perf YTD	-73.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-81.97%	Beta	-
Dividend TTM	-	Quick Ratio	17.63	Sales past 5Y	0.00%	Gross Margin	-	52W Low	13.48%	ATR (14)	2.23
Dividend Ex-Date	-	Current Ratio	17.63	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	22.07	Volatility	14.12% 9.03%
Employees	-	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.67	Target Price	6.33
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-36.08%	Payout	-	Rel Volume	2.36	Prev Close	4.47
Sales Surprise	-	EPS Surprise	-889.95%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	650.50K	Price	4.80
SMA20	-71.20%	SMA50	-76.37%	SMA200	-76.35%	Trades		Volume	1,538,429	Change	7.38%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
04:30PM	Loading…
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
09:10PM	Loading…
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pande Vijay Satyanand	Director	Oct 01 '24	Buy	19.73	126,793	2,501,626	1,026,793	Oct 03 07:19 PM
Pande Vijay Satyanand	Director	Oct 02 '24	Buy	19.73	67,096	1,323,804	1,093,889	Oct 03 07:19 PM
Pande Vijay Satyanand	Director	Oct 03 '24	Buy	19.90	25,306	503,589	1,119,195	Oct 03 07:19 PM
Cormorant Asset Management, LP	Former 10% Owner	Sep 27 '24	Buy	18.00	450,000	8,100,000	1,629,529	Oct 01 04:01 PM
Pande Vijay Satyanand	Director	Sep 27 '24	Buy	18.00	900,000	16,200,000	900,000	Sep 27 04:28 PM
ENRIGHT PATRICK G	Director	Sep 27 '24	Buy	18.00	400,000	7,200,000	1,710,589	Sep 27 04:26 PM
HEALY JAMES	Director	Sep 27 '24	Buy	18.00	666,665	11,999,970	2,227,124	Sep 27 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BioAge Labs Inc

Upgrade your FINVIZ experience